Turkish Validation of the Nijmegen Questionnaire in COPD
ConditionCOPD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSaglik Bilimleri Universitesi
About this trial
Dysfunctional breathing is a common and clinically relevant problem in patients with chronic obstructive pulmonary disease (COPD), contributing to increased dyspnea perception, reduced exercise tolerance, and impaired quality of life. The Nijmegen Questionnaire (NQ) is a widely used symptom-based instrument for screening dysfunctional breathing; however, a validated Turkish version for patients with COPD is currently unavailable.
This observational methodological study aims to translate, culturally adapt, and evaluate the validity and reliability of the Turkish version of the Nijmegen Questionnaire (NQ-TR) in individuals with stable COPD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 years and older
Diagnosis of COPD confirmed according to GOLD criteria
Clinically stable disease (no acute exacerbation or hospitalization within the last 4 weeks)
Ability to read and understand Turkish
Disqualifiers
Acute COPD exacerbation or respiratory infection within the previous 4 weeks
Presence of severe cardiac, neurological, or systemic disease affecting questionnaire responses
Coexisting pulmonary conditions such as bronchiectasis, lung cancer, prior pulmonary tuberculosis, pleural disease, or history of lung surgery
Moderate to severe cognitive impairment or communication difficulties
Trial population
The study population consists of adults aged 18 years and older with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD criteria. Eligible participants are clinically stable patients attending the pulmonology outpatient clinic of a tertiary care hospital, with no acute exacerbation or hospitalization within the previous four weeks. All participants are Turkish-speaking, able to complete self-reported questionnaires, and provide written informed consent.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Questionnaires
Other interventionAdministration of validated self-reported questionnaires (Nijmegen Questionnaire, CAT, mMRC, HADS, Dyspnea-12)
Treatment groups
90 Participants
are divided into 1 treatment groupGroup A: COPD1 intervention
Trial outcomes
Primary outcomes
1
Turkish version of the Nijmegen Questionnaire (NQ-TR)
The Nijmegen Questionnaire is a validated self-report instrument used to assess symptoms related to dysfunctional breathing and hyperventilation. It consists of 16 items evaluating the frequency of respiratory and non-respiratory symptoms, with higher total scores indicating greater symptom severity. In this study, the Turkish-validated version of the Nijmegen Questionnaire (NQ-TR) will be used to evaluate dysfunctional breathing symptoms in participants.
Time frame
Baseline and 1 weekSecondary outcomes
1
COPD Assessment Test (CAT)
The COPD Assessment Test (CAT) is a validated, patient-completed questionnaire designed to assess the impact of chronic obstructive pulmonary disease (COPD) on health status. It consists of 8 items covering symptoms, activity limitation, and overall well-being, with total scores ranging from 0 to 40. Higher scores indicate a greater impact of COPD on health status. In this study, the Turkish-validated version of the COPD Assessment Test (CAT) will be used to evaluate disease-related symptom burden and health status in participants with COPD.
Time frame
Baseline2
Modified Medical Research Council (mMRC) Dyspnea Scale
The Modified Medical Research Council (mMRC) Dyspnea Scale is a widely used, validated scale for assessing the severity of perceived breathlessness related to physical activity in individuals with chronic respiratory diseases. The scale grades dyspnea from 0 to 4, with higher grades indicating greater functional limitation due to breathlessness. In this study, the Turkish-validated version of the Modified Medical Research Council (mMRC) Dyspnea Scale will be used to assess dyspnea severity in participants.
Time frame
Baseline3
Dyspnea-12 (D-12) Scale
The Dyspnea-12 (D-12) Scale is a validated patient-reported outcome measure designed to assess both the physical and affective components of breathlessness. It consists of 12 items, with total scores ranging from 0 to 36, where higher scores indicate greater dyspnea severity. In this study, the Turkish-validated version of the Dyspnea-12 (D-12) Scale will be used to evaluate the multidimensional severity of dyspnea in participants.
Time frame
Baseline4
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a validated self-report questionnaire designed to assess symptoms of anxiety and depression in individuals with physical health conditions. It consists of 14 items divided into two subscales: anxiety (HADS-A) and depression (HADS-D), each comprising 7 items, with subscale scores ranging from 0 to 21. Higher scores indicate greater psychological distress. In this study, the Turkish-validated version of the Hospital Anxiety and Depression Scale (HADS) will be used to evaluate anxiety and depression levels in participants.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov